Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Ishan RoyGordon SmilnakMadelyn BurkartElizabeth HamiltonKatherine ThorpSarah MiyataShuo MaBarbara ProJane WinterLeo GordonReem KarmaliPublished in: British journal of haematology (2022)
Cachexia is a muscle-wasting syndrome that is known to impact the clinical course of several cancer populations but has not been specifically investigated in patients receiving chimeric antigen receptor T (CAR-T) cell therapy. In this study, we investigated the relationship between cachexia markers and several cancer and functional outcomes in a pilot population of aggressive B-cell non-Hodgkin lymphoma patients receiving CAR-T. We found that the prognostic nutritional index was linked to progression-free survival, overall survival, and disability-free survival, while several additional weight and serum-based markers of cachexia were also associated with negative outcomes. These data prompt further investigation of cachexia markers in populations receiving CAR-T cell therapy.
Keyphrases
- cell therapy
- free survival
- papillary thyroid
- stem cells
- mesenchymal stem cells
- squamous cell
- multiple sclerosis
- body mass index
- physical activity
- skeletal muscle
- type diabetes
- atomic force microscopy
- clinical trial
- weight loss
- randomized controlled trial
- childhood cancer
- adipose tissue
- study protocol
- machine learning
- case report
- metabolic syndrome
- genetic diversity
- deep learning
- data analysis
- glycemic control